Rituximab found to extend progression-free survival in indolent lymphoma
New trial results have been published showing that a combination of Celgene’s Revlimid and Roche’s rituximab significantly extended progression-free survival in patients with relapsed or refractory indolent lymphoma, compared to rituximab with placebo.
Read More
